Adoptive transfer of tumor-reactive T cells into cancer patients with the intent of inducing a cytotoxic antitumor effector response and durable immunity has long been proposed as a novel therapy for a broad range of malignancies [88, 89] The introduction of genes, adoptive cellular therapy, involves the encoding of artificial receptors known as chimeric antigen receptors (CARs). Here, CARS1 is linked to cancer.